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Abstract
Inactivation of the von Hippel–Lindau (VHL) gene and activation of the hypoxia-inducible factor (HIF) in susceptible cells precedes forma-
tion of tumorlets and frank tumor in the epididymis of male VHL patients. We performed detailed histologic and molecular pathologic
analysis of tumor-free epididymal tissues from VHL patients to obtain further insight into early epididymal tumorigenesis. Four epididy-
mides from two VHL patients were serially sectioned to allow for three-dimensional visualization of morphologic changes. Areas of in-
terest were genetically analyzed by tissue microdissection, immunohistochemistry for HIF and markers for mesonephric differentiation,
and in situ hybridization for HIF downstream target vascular endothelial growth factor. Structural analysis of the epididymides revealed
marked deviations from the regular anatomic structure resulting from impaired organogenesis. Selected efferent ductules were repre-
sented by disorganized mesonephric cells, and the maldeveloped mesonephric material was VHL-deficient by allelic deletion analysis.
Furthermore, we observed maldeveloped mesonephric material near cystic structures, which were also VHL-deficient and were apparent
derivatives of maldeveloped material. Finally, a subset of VHL-deficient cells was structurally integrated in regular efferent ductules; pro-
liferation of intraductular VHL-deficient cells manifests itself as papillary growth into the ductular lumen. Furthermore, we clarify that that
there is a pathogenetic continuum between microscopic tumorlets and formation of tumor. In multiple locations, three-dimensional re-
construction revealed papillary growth to extend deeply into ductular lumina, indicative of progression into early hamartoma-like neopla-
sia. We conclude epididymal tumorigenesis in VHL disease to occur in two distinct sequential steps: maldevelopment of VHL-deficient
mesonephric cells, followed by neoplastic papillary proliferation.
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Introduction
von Hippel–Lindau (VHL) disease is a tumor-suppressor gene syn-
drome that causes pathologic changes in central and peripheral nervous
systems and retina, kidney, pancreas, adrenal glands, vestibular aque-
duct, and the epididymis. The epididymis frequently develops a benign
tumor, epididymal cystadenoma [1,2]. Consistent with Knudson’s
“two-hit hypothesis”, patients with VHL disease carry a germ line mu-
tation of the VHL gene [3]. Inactivation of the other, wild type copy of
the VHL gene in susceptible cells within the epididymis has been asso-
ciated with cystadenoma development [4]. With this study, we further
characterize the cells in which the “second hit,” responsible for knock-
out of VHL protein function, occurs.
In recent studies on nervous system tissues of VHL patients, we
suggest that VHL tumorigenesis is preceded by developmental changes
and propose that the structural and topographic complexity of the
pathologic changes can only be explained by VHL inactivation of se-
lected cells during CNS development [5,6]. Because of the relatively
large size of the human central and peripheral nervous system, how-
ever, detailed analysis requires extensive sampling of tissues [5], and
various sites of CNS tumorigenesis remain poorly understood. In con-
trast, tumorigenesis in human epididymis seems to be restricted to the
efferent ductule compartment [4], an anatomic structure of approxi-
mately 1 cm3 in size. In the epididymis, therefore, the effects of VHL
deficiency on the entire organ can be analyzed in unprecedented detail.
von Hippel–Lindau disease–associated early pathologic changes
within the nervous system and outside the nervous system show fun-
damental differences. Within the nervous system, the earliest detect-
able changes have been characterized as vascularized “mesenchymal
tumorlets” [5,6]; in contrast, early changes in the epididymis are
characterized as cystic or papillary “epithelial tumorlets” [4]. The
“mesenchymal tumorlets” in the CNS have been shown to have
the potential of progressing into VHL-deficient mesenchyme and
tumor [5]. Whereas epithelial tumorlets in the epididymis have been
shown to be VHL-deficient [4], it has never been clarified whether
microscopic structural changes are pathogenetically distinct from
frank tumors or whether they represent a pathogenetic continuum.
With this study, we attempted to identify and characterize different
types of mesonephric maldevelopment in VHL epididymis to pro-
vide direct evidence that tissue maldevelopment is pathogenetically
linked to tumorigenesis.
Materials and Methods
Tissue
Four grossly intact epididymides were procured at autopsy of two
adult male VHL patients. One patient had died at 40 years from
acute renal failure after bilateral nephrectomy for renal cell carci-
noma and pheochromocytoma. He had developed cerebellar heman-
gioblastomas, bilateral endolymphatic sac tumors, and pancreatic
microcystic adenoma. The other patient had died at 43 years from
intracerebral hemorrhage, with a clinical history of cerebellar and spi-
nal cord hemangioblastomas and bilateral renal cell carcinoma. Most
of each epididymis was procured for this study, whereas smaller parts
were retained at the Laboratory of Pathology, National cancer Insti-
tute, for diagnostic purposes. Research material was fixed in formalin
and processed into paraffin blocks. Each paraffin block containing
efferent ductules was serially sectioned. Of the serial sections, at least
every 10th section was stained with hematoxylin and eosin (H&E)
for morphologic evaluation. This approach allowed reconstruction
of anatomic changes in three dimensions. In addition, adjacent sec-
tions were available from each microscopic structure of interest for ad-
ditional immunohistochemical or molecular pathologic investigations.
Immunohistochemistry
Immunohistochemistry on paraffin sections was performed using
anti-CD31 (DAKO, Carpinteria, CA; 1:20 dilution; predigestion
with protease I) and cytokeratin cocktails HMWK (DAKO; 1:100
dilution; heat-induced epitope retrieval), AE1/AE3 (DAKO; 1:80
dilution; predigestion with protease I), and MAK6 (Zymed, South
San Francisco, CA; 1:2 dilution; predigestion with protease I). Im-
munohistochemistry was performed on a Ventana ES using an I-view
detection kit (Ventana, Tucson, AZ).
A modified protocol was used for the detection of hypoxia-inducible
factors HIF1 and HIF2. For antigen retrieval, sections were immersed
in preheated Dako target retrieval solution in a pressure cooker for
90 seconds. Primary antibodies were mouse monoclonal antihuman
HIF1α H1α67 (Neomarkers, Fremont, CA) 1/1000 and rabbit poly-
clonal antimouse HIF2α PM8 antiserum [7], 1/10,000. Primary anti-
body was omitted for negative controls. Antigen/antibody complexes
were revealed by means of the Catalyzed Signal Amplification system
(DAKO; HIF) or Envision system (DAKO; CAIX) according to the
manufacturer’s instructions. Sections were counterstained with hema-
toxylin for 15 seconds, dehydrated in graded ethanol washes, and
mounted in p-xylene-bis-pyridinium bromide permount (Lamb, East-
bourne, UK).
The following protocol was used for the detection of AE1/3,
HMWK (Dakocytomation, Carpinteria, CA), and MAK6 (Zymed)
on paraffin sections. For antigen retrieval, sections were treated with
DAKO Target Retrieval Solution (DAKO) and incubated at 95°C
for 20 minutes. Sections were cooled at room temperature and
washed three times in PBS. After three washes in PBS, sections were
incubated in 10% horse serum for 1 hour. The primary antibody
was diluted in 2% horse serum, and the sections were incubated in
a humidified chamber at 4°C overnight. The sections were then
incubated with secondary antibody and avidin-biotin complex for
1 hour each. The reaction product was visualized with diaminoben-
zidine (DAB). A 30-second counterstaining with Mayer’s hematoxy-
lin followed. Sections were dehydrated by graded ethanol washes of
95% and 100% and were washed with xylene before being mounted.
In Situ Hybridization
The cDNA encoding human vascular endothelial growth factor
(VEGF) was cloned into a SK2 Bluescript plasmid (Stratagene,
La Jolla, CA) using HindIII and EcoRI as restriction sites [8]. The
digoxigenin (DIG) probes were transcribed in sense and antisense di-
rections using T3 and T7 RNA polymerase, respectively. This protocol
is based on the Roche manual [9]. In brief, after deparaffinization
and rehydration, sections were refixed in 4% paraformaldehyde for
20 minutes, washed with TBS, immersed in 0.2 M hydrochloric acid
for 10 minutes, and washed again with TBS. The sections were treated
with 0.5% acetic anhydride in 100 mM Tris (pH 8.0) for 10 minutes
then washed with TBS. The sections were transferred into a Proteinase
K solution and digested for 20 minutes at 37°C. The sections were
washed with TBS, and the reaction was stopped by incubation in
TBS at 4°C for 5 minutes. After dehydration with ethanol, the sections
were rinsed briefly with chloroform and placed in a humid chamber at
55°C for 30 minutes. Digoxigenin-labeled VEGF antisense probes
were then applied to the tissues. Both DIG-labeled sense probes and
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no primary probes were used as negative controls. The sections were
placed on a hot plate at 95°C for 4 minutes and incubated in a humid
chamber at 55°C overnight. The sections were washed with 2× SSC
at room temperature, with 1× SSC with 50% deionized formamide
at 55°C, with 1× SSC at room temperature and finally with TBS.
The sections were incubated with blocking reagent containing 10%
Fraction V albumin for 15 minutes. The sections were next incubated
with alkaline phosphatase–conjugated anti-DIG antibody for 60 min-
utes, followed by washing with TBS and then application of NBT/
BCIP color reagent for visualization at 4°C overnight. The sections
were counterstained with BC-50 Red Counterstain (Biomeda, Foster
City, CA). The presence and intensity of DIG antibody expression
were examined in conjunction with the serial H&E sections.
Microdissection and Deletion Analysis
Tissue sections taken from formalin-fixed, paraffin-embedded tis-
sue blocks were placed on glass slides and used for microdissection
and loss of heterozygosity (LOH) analysis. The sections were con-
secutive to those investigated by H&E staining. Microdissection
was performed under direct light microscopic visualization using a
30-gauge needle as previously described [4].
Control samples were obtained from normal epididymis tissue
on the same histologic slide. Procured cells were immediately re-
suspended in 10 to 30 μl of buffer containing Tris/HCl, pH 8.0,
10 mM ethylenediamine tetra-acetic acid, pH 8.0, 1% Tween 20,
and 0.1 mg/ml proteinase K and were incubated at 37°C for 3 days.
The mixture was boiled for 10 minutes to inactivate proteinase K,
and 2 μl of this solution was used for the polymerase chain reaction
amplification of DNA.
The samples were analyzed for LOH with the microsatellite mark-
ers D3S1038 and D3S1110 (Invitrogen, Carlsbad, CA), flanking the
VHL gene on chromosome 3p25. Polymerase chain reaction was per-
formed for 38 cycles: denaturing at 95°C for 45 seconds, annealing
at 55°C for 45 seconds, and extending at 72°C for 45 seconds. For all
primers, the final extension was continued for 10 minutes at 72°C.
Each PCR sample contained 2 μl of template DNA as noted above,
10 pmol of each primer, 20 nmol each of dATP, dCTP, DGTP, and
DTTP, 15 mM MgCl2, 1.25 U of Taq DNA polymerase, 0.2 μl
of [32P] dCTP (6000 Ci/mmol), and 1 μl of 10× buffer in a total
volume of 10 μl. Labeled amplified DNA was mixed with 6 μl of
formamide loading dye (95% formamide, 20 mM EDTA, 0.05%
bromophenol blue, 0.05% xylene cyanol) and analyzed on a poly-
acrylamide gel. The samples were denatured for 10 minutes at 95°C
and loaded onto a gel consisting of 6% acrylamide (49:1 acrylamide/
bis), 5% glycerol, and 0.6× TBE. Samples were electrophoresed at
60 W at room temperature for 1.5 hours. Gels were transferred to a
3-mmWhatman paper and dried, and autoradiography was performed
with Kodak X-OMAT film (Eastman Kodak, Rochester, NY).
Results
The Epididymis in Male VHL Patients Shows Maldeveloped
Mesonephric Material
Histologic examination of epididymis tissue revealed marked de-
viations from regular anatomic structure of the efferent ductules. The
efferent ductule compartment of regular epididymis is composed of
15 to 20 convoluted ductules [10], and all epithelial cells are inte-
grated within these ductules. In contrast, VHL epididymis displayed
areas of diffusely scattered clear cells, arranged in isolation or small
clusters, consistent with maldeveloped mesonephric material (Fig-
ure 1, A and B). Parts of individual ductules were represented by dif-
fusely scattered clear cells, arranged isolated or in small clusters
(Figure 1B). This evidence of incomplete; developmentally arrested
efferent ductule formation is consistent with Arvid Lindau’s original
hypothesis that disturbances of development in the mesoderm lead
to failure in the integration between mesodermal and epithelial com-
ponents [2,11].
Immunohistochemical analysis of maldeveloped cells with MAK6,
AE1/AE3, and HMWK showed an immunophenotype that was
similar to that of mature efferent ductules, which is consistent with
previous observations that mesonephric material and mature nephrons
share immunophenotypic features (Figure 1, C–E ) [12]. Reticulin
stain revealed isolated cells and cell clusters to be separated by mature
reticulin fibers (Figure 1F ), anatomically distinct from the mature
ductular system in which whole ductules are surrounded by reticulin
fibers. Thus, disorganized cell clusters maintain a mesenchymal archi-
tecture having failed to form mature epithelial ductules.
Maldeveloped Mesonephric Material Is VHL-Deficient
Hypoxia-inducible factor immunohistochemistry and VEGF
in situ hybridization revealed positive signal in maldeveloped meso-
nephric material (Figures 1, G and H , and 2). Immunoreactivity with
anti-HIF2 seemed stronger compared to anti-HIF1 in maldeveloped
mesonephric material (Figures 1, G and H , and 2). Diffuse mesen-
chymal cell accumulations were microdissected and subjected to
LOH analysis of the VHL gene locus using primers D3S1110 and
D3S1038 flanking the VHL gene locus. We identified LOH in dis-
organized mesonephric material (Figure 1I ). Therefore, the disorga-
nized mesonephric material is VHL-deficient, and VHL deficiency
seems directly associated with structural maldevelopment.
Maldeveloped Mesonephric Material Is Associated with
Cyst Formation
Within or at the border of disorganized maldeveloped mesonephric
material, we frequently detected cystic-tubular structures, i.e., closed
alignments of epithelial cells around an open central space (Figure 2,
A and B). In contrast to mature ductules, however, cysts lacked the
characteristic undulating cytologic architecture [10] and were not cili-
ated. By immunohistochemistry, the cytokeratin expression profile was
similar in maldeveloped mesonephric material, cystic-tubular struc-
tures, and mature ductules. Microdissection and deletion analysis of
cystic-tubular structures consistently revealed LOH of the VHL gene
locus (data not shown). Therefore, a subset of VHL-deficient cells is
capable of forming primitive cystic-tubular structures.
Hypoxia-inducible factor immunohistochemistry and VEGF in situ
hybridization revealed positive signal in cystic-tubular structures (Fig-
ure 2, C–F). Similar to our observations in maldeveloped mesonephric
material, immunoreactivity with anti-HIF2 seemed stronger compared
to anti-HIF1. Three-dimensional reconstruction revealed some cysts
to be parts of large tubular structures extending deep into the tis-
sue block, suggestive of immature and incomplete efferent ductule
formation (data not shown). Focally, cystic epithelium revealed papil-
lary proliferation.
VHL-Deficient Intraductular Cells Reveal
Papillary Proliferation
Not all VHL-deficient cells constitute VHL-deficient maldeveloped
mesonephric material or VHL-deficient cystic-tubular structures.
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Instead, a significant number of VHL-deficient cells are integrated
within the mature, VHL-competent ductular system (Figures 3 and
4D). Proliferation of intratubular VHL-deficient cells was frequently
identified as papillary proliferation, i.e., cellular proliferation accom-
panied by reactive fibrovascular proliferation [4]. Proliferative cells were
positive for HIF by immunohistochemistry; notably, the intensity of
the HIF1 signal was similar to that of the HIF2 signal (Figure 3) in
contrast to diversely intense HIF1 and HIF2 signals observed in mal-
developed material and cysts.
Three-dimensional reconstruction revealed most papillary prolif-
erations to be less than 100 μm in size. In other instances, however,
three-dimensional reconstruction allowed us to trace isolated events
of papillary formation into larger structures and visualize the anat-
omy of the structure in toto (Figure 5). Larger structures were char-
acterized by deep invaginations of polarized VHL-deficient cells into
the ductular system, accompanied by a core of nourishing fibrovas-
cular stroma (Figure 5).
Discussion
von Hippel–Lindau disease elicits an abundance of microscopic
foci of cellular proliferation in a selective set of target organs, in-
cluding the nervous system [5,6], kidney [13,14], epididymis [4],
and endolymphatic sac and duct [15]. Morphologically, these cellular
proliferations have been identified as mesenchymal tumorlets in the
nervous system [5,6] or as epithelial tumorlets in target organs out-
side the nervous system [4,15]. Our detailed analysis of epididymal
tissue from VHL patients provides evidence that microscopic tumor-
lets are composed of developmentally arrested mesonephric cells.
This finding implies that the “second hit”—inactivation of the wild
type VHL allele—occurs in mesonephric cells during development
of the epididymis.
The multifocality and diversity of microscopic developmental
changes (Figure 4) can be explained as a result of coproliferation and
codevelopment of VHL-deficient and VHL-competent mesoneph-
ric cells. In the VHL epididymis, VHL-deficient mesonephric cells
Figure 1. (A) Efferent ductule compartment of tumor-free VHL epididymis, H&E stain. Different efferent ductules are separated by
dotted lines. The arrow points to an area of maldeveloped mesonephric material. Arrowheads show multifocal events of intratubular
papillary proliferation as previously described [4]. (B) Higher magnification of maldeveloped mesonephric material, characterized by
diffusely scattered mesonephric cells, arranged either in isolation or in small clusters. Mesonephric material is immunoreactive with
cytokeratin cocktails MAK6 (C), AE1/AE3 (D), and HMWK (E). (F) Reticulin stain reveals sequestration of maldeveloped mesonephric
cells and cell clusters. Mesonephric cells reveal activation of HIF2 (G) and HIF1 (H) with stronger signal for HIF2 compared with
HIF1. (I) Deletion analysis of maldeveloped mesonephric material (MMM) using markers D3S1110 and D3S1038 reveals LOH of
wild type VHL allele compared with normal epididymal tissue (N). Arrowheads point to the position of both VHL alleles for the respec-
tive markers.
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may persist in isolation, as small VHL-deficient cell clusters or as
VHL-deficient cystic-tubular structures (Figures 1, 2, and 4). Some
VHL-deficient mesonephric cells, however, are assembled within VHL-
competent efferent ductules (Figures 3 and 4). Thus, VHL inactiva-
tion in a subset of mesonephric cells during organogenesis results in a
different anatomic structure of the efferent ductules in VHL disease.
The generation of tumorlets, in contrast, is the result of the prolif-
erative capacity of VHL-deficient mesonephric cells. Proliferation of
cystic or intraductular VHL-deficient cells may generate papillary struc-
tures, secondary to recruitment of fibrovascular tissue which supports
the expanding surface of proliferating single-layered VHL-deficient
cells. Recruitment of fibrovascular tissue is certainly facilitated by the
continuous up-regulation of hypoxic stress proteins including HIF,
GLUT-1, and VEGF in VHL-deficient mesonephric cells.
Our findings suggest that developing mesonephric cells are pri-
marily targeted in VHL disease and represent cells that have the po-
tential for neoplasia. During human embryogenesis, VHL mRNA is
prominently expressed in mesonephric tubules, suggesting a role for
the VHL gene in early cellular differentiation [16]. How exactly loss
of VHL gene function is linked to cellular differentiation, matura-
tion, and migration has remained elusive. The VHL protein is part
of a multiprotein complex targeting proteins for ubiquitin-mediated
degradation [17–19], including HIFα subunit proteins. A possible
role for developmental arrest may therefore be played by HIF, which
is constitutively activated and stabilized after loss of VHL function
[20–22] and consistently present in the smallest tumor precursor
structures [4,5]. Similarly, a role for developmental arrest may also
be played by HIF target proteins VEGF, GLUT-1, and CAIX [20,
23,24] that have been shown to be expressed in the earliest steps
of VHL tumorigenesis [4,5].
There is also emerging evidence that HIF is constitutively active
in mesonephric mesenchyme and that VEGF is up-regulated before
mesenchymal to epithelial transition [25]; in contrast, expression
of these markers is undetectable in mature ductal cells. It could
Figure 2.Maldeveloped mesonephric material is associated with cyst formation (A, B; see arrows). Maldeveloped mesonephric material
as well as cyst material is VHL-deficient and shows activation of HIF2 (C) and HIF1 (D). (E) In situ hybridization with VEGF antisense probe
shows expression of VEGF in maldeveloped mesonephric material (arrows) as well as associated cysts; (F) negative control with VEGF
sense probe.
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Figure 3. VHL-deficient cells, integrated in mature efferent ductular epithelium, show different stages of papillary growth. Immunohis-
tochemistry for HIF1 and HIF2 was performed on consecutive sections. von Hippel–Lindau–deficient mesonephric cells (identified by
immunoreactivity with anti-HIF) accumulate within normal efferent ductules (left, middle) before formation of frank papillary structures
(right). The intensity of the HIF1 signal appears similar to that of HIF2 signal.
Figure 4. Basic structural-anatomic changes in VHL epididymis. Primary developmental changes are characterized by scattered deposits
of VHL-deficient maldeveloped mesonephric cells (A), associated with VHL-deficient tubular structures that appear as cysts in individual
sections (B); papillary growth is initiated from tubular/cyst wall epithelium (C) or from VHL-deficient cells that are integrated in regular
efferent ductular structures (D).
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therefore be argued that up-regulation of HIF and VEGF in VHL-
deficient mesonephric material may be associated with its primitive
developmental state. The key event associated with developmental
arrest may therefore not be the up-regulation of hypoxic stress but
the failure to down-regulate it. Pathologic persistence of HIF and
VEGF may therefore be associated with functional impairment of
the affected cells’ developmental program. Immortalization, combined
with incapacity of terminal differentiation, seems to be a condicio sine
qua non for tumorigenesis. It remains to be shown under which con-
ditions these prerequisites are associated with cellular proliferation.
Whereas immature mesonephric material and cysts may primarily
represent maldeveloped anatomic structures, papillary formation is
indicative of pathologic cellular proliferation. Applying consistent con-
centrations of HIF1 and HIF2 antibodies, we consistently detected
increased HIF2 signal compared with HIF1 signal in maldeveloped
structures consistent with the recent observation of contrasting prop-
erties of HIF1 and HIF2 in VHL disease–associated renal lesions [26]
(Figures 1 and 2). In areas of papillary proliferation, however, HIF1 and
HIF2 signal intensities were less distinct (Figure 3), possibly indicating
increased HIF1 activation to be associated with proliferative activity.
We have shown that VHL inactivation of a subset of mesonephric
cells causes maldeveloped anatomic structure in epididymal tissue
of VHL patients. We also demonstrated that maldevelopment can
be followed by limited papillary proliferation creating a pathologic
tumorlet structure. Three-dimensional reconstruction revealed a sub-
set of papillary events to be associated with extensive neoplastic
growth into the efferent ductular system, and extrapolation of this
process to a later time point in time would predict a tumor with
tightly intermingled neoplastic and preexistent anatomic structures
(Figure 5). The distinctive intraductular extension of VHL-deficient
cells is reminiscent of hamartomatous structures that have been de-
fined as “localized, disordered differentiation during embryonic de-
velopment” [27] or as tissues that have been “wrongly assembled
in the course of development” [28]. At the same time, however,
hamartomatous cells are defined as “nonneoplastic” [29], “mature”
[30], or “adult” [31], which seems inconsistent with our identifi-
cation of developmentally arrested mesonephric cells, proliferation
of which constitutes epididymal neoplasia.
Whatever the accurate terminology for early VHL tumorigenesis
may be, we propose it to occur in two distinct pathogenetic stages.
The first stage is characterized by developmental arrest of VHL-
deficient cells with subsequent structural-anatomic alterations of
the epididymal tissue. The second stage is characterized by slow
proliferation of a subset of VHL-deficient cells with activation/
up-regulation of HIF and VEGF, associated with continuous reactive
fibrovascular proliferation.
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